<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02613286</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE: 42981715.7.0000.5205</org_study_id>
    <secondary_id>U1111-1176-6929</secondary_id>
    <nct_id>NCT02613286</nct_id>
  </id_info>
  <brief_title>LESs Surgical Radicality for EaRly Stage Cervical Cancer</brief_title>
  <acronym>LESSER</acronym>
  <official_title>A Proof of Concept Non-inferiority Trial Evaluating the Safety and Efficacy of Extrafascial Hysterectomy Plus Pelvic Lymph-node Dissection in Patients With Stage IA2-IB1 Cervical Cancer ≤ 2cm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Câncer de Pernambuco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Santa Casa de Misericórdia de Maceió</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Professor Fernando Figueira Integral Medicine Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Câncer de Pernambuco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, multicenter, randomized, phase II non-inferiority trial (proof&#xD;
      of concept study). Its purpose is to evaluate the safety and efficacy of extrafascial&#xD;
      hysterectomy plus pelvic-lymph node dissection compared with the standard modified radical&#xD;
      hysterectomy in patients with stage IA2-IB1 cervical cancer ≤ 2cm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of extrafascial hysterectomy&#xD;
      compared with modified radical hysterectomy, both plus level 1 pelvic lymph-node dissection,&#xD;
      in patients with early stage IA2-IB1 cervical cancer ≤ 2cm. The experimental procedure will&#xD;
      be considered to be promising for treatment of stage IA2-IB1 cervical cancer ≤ 2cm if the&#xD;
      Bayesian posterior probability of &quot;the difference of the 3-y DFS rate is less than the&#xD;
      non-inferiority margin of 5%&quot; is at least 50%. Thus, using this proof of concept design, the&#xD;
      planned sample size is 40, with 20 cases per arm, which provides 72% chance of satisfying the&#xD;
      above criteria, under the hypothesis that the lowest 3-y DFS rate in each arm is 90%. As&#xD;
      required, adjuvant therapy will include cisplatin-based chemo-radiation or pelvic radiation&#xD;
      alone (EBRT +/- intracavitary brachytherapy) indicated according to the #GOG92 and #GOG109&#xD;
      criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Proof of concept design (phase II non-inferiority trial)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>3-y DFS</time_frame>
    <description>Time from surgery to recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events (surgical)</measure>
    <time_frame>90 days</time_frame>
    <description>Surgical morbidity and mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported QoL</measure>
    <time_frame>Base-line, 30-90 days, 4-6 months</time_frame>
    <description>QoL according to EORTC C30 questionnaire (v3.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of using adjuvant therapy</measure>
    <time_frame>90 days</time_frame>
    <description>Cisplatin-based chemo-radiation or pelvic radiation alone (EBRT +/- intracavitary brachytherapy) indicated according to the #GOG92 and #GOG109 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to starts adjuvant therapy</measure>
    <time_frame>90 days</time_frame>
    <description>Time to starts adjuvant therapy (if needed)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <arm_group>
    <arm_group_label>Extrafascial Hysterectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Type A hysterectomy with 1 - 2cm of vaginal cuff plus level 1 pelvic lymph-node dissection according to Querleu and Morrow classification.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modified radical hysterectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Type B2 hysterectomy with 1 - 2cm of vaginal cuff plus level 1 pelvic lymph-node dissection according to Querleu and Morrow classification.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Extrafascial Hysterectomy</intervention_name>
    <description>Hysterectomy plus Pelvic Lymph-Node Dissection</description>
    <arm_group_label>Extrafascial Hysterectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Modified radical hysterectomy</intervention_name>
    <description>Hysterectomy plus Pelvic Lymph-Node Dissection</description>
    <arm_group_label>Modified radical hysterectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically confirmed adenocarcinoma, squamous, or adenosquamous&#xD;
             cancer of the cervix by LEEP, cone or cervical biopsy;&#xD;
&#xD;
          2. Aged between 18 and 70 years;&#xD;
&#xD;
          3. performance status 0-2 (ECOG, Eastern Cooperative Oncology Group) and / or greater&#xD;
             than 70 points by the Karnofsky scale;&#xD;
&#xD;
          4. FIGO early stage IA2-IB1 ≤ 2cm;&#xD;
&#xD;
          5. Appropriated cardio-respiratory, hepato-renal and hematological reserves; and&#xD;
&#xD;
          6. Signing of the Consent Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Limiting systemic comorbidities including neuro-psychiatric disorders or obesity;&#xD;
&#xD;
          2. Apparent or confirmed uncontrolled infections;&#xD;
&#xD;
          3. Other malignancies in activity;&#xD;
&#xD;
          4. Previous radiation or chemotherapy treatment or major pelvic surgery;&#xD;
&#xD;
          5. History of drug allergies, and pregnancy or breast feeding; and&#xD;
&#xD;
          6. Evidence of more extensive disease at the time of surgery.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 20, 2015</study_first_submitted>
  <study_first_submitted_qc>November 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Câncer de Pernambuco</investigator_affiliation>
    <investigator_full_name>Thales Paulo Batista</investigator_full_name>
    <investigator_title>Consultant Physician and Researcher (Surgical Oncology)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

